EMPOWERING DIABETES CARE DURING PREGNANCY: UNLEASHING THE POTENTIAL OF CGM (AS-109)

Friday, October 27, 2023

07:15 – 08:15 EST

Location: Palais, 517D

Target Audience: Endocrinologists, Diabetologists, Internists, Family Physicians, Allied Health Professionals, Residents

Chair : AS(s)

Denice Feig, MD

Clinician Scientist
Mount Sinai Hospital
University of Toronto

Presenter : AS(s)

AD

Amy Dunlop, RN, MSc, CDE (she/her/hers)

Clinical Research Nurse, RN, MSc, CDE
University of Calgary
ER

Elizabeth Rosolowsky
Jennifer M. Yamamoto, MD, MSc, FRCPC

Assistant Professor
University of Manitoba
University of Manitoba

Disclosure(s):

Denice Feig, MD: No relevant disclosure to display

Amy Dunlop, RN, MSc, CDE: Medtronic: Employment (Ongoing); Tandem Diabetes Care, Canada: Employment (Ongoing)

Jennifer M. Yamamoto, MD, MSc, FRCPC: Abbott: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing); American Diabetes Association: Speaker/Honoraria (Terminated); CIHR: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Diabetes Canada: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); HSC Foundation: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Medtronic: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing)

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

describe the outcomes associated with utilizing continuous glucose monitoring (CGM) devices during pregnancy; and
identify ways in which CGM supports the management of diabetes during pregnancy by exploring its practical applications in clinical practice

This program was co-developed by the Canadian Society of Endocrinology and Metabolism and Dexcom and was planned to achieve scientific integrity, objectivity, and balance.